+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Surveillance for patients with clinical stage I nonseminomatous testicular germ cell tumors



Surveillance for patients with clinical stage I nonseminomatous testicular germ cell tumors



World Journal of Urology 33(9): 1351-1357



To assess the prognostic value of histological parameters in patients with clinical stage I nonseminomatous germ cell tumors (NSGCTs) undergoing active surveillance post-orchiectomy. Prognoses and recurrence patterns were investigated in 78 patients with CSI NSGCT who underwent orchiectomy. Immediately following orchiectomy, patients participated in active surveillance between 1999 and 2013 at Sun Yat-sen University Cancer Center, Guangzhou, China. 23.1 % of the 78 investigated patients with CSI NSGCT relapsed, within a median time of 5.6 months It was determined using multivariate analysis that lymph vascular invasion (LVI) (OR 6.521; 95 % CI 1.872-22.721; p = 0.003) and the predominant presence of yolk sac tumor (greater than 50 %) (OR 3.537; 95 % CI 1.076-11.628; p = 0.038) independently correlated with relapse-free survival (RFS). Patients were categorized accordingly into three risk groups: low risk [<50 % presence of yolk sac tumor and LVI (-); n = 41], intermediate risk [50 % or greater presence of yolk sac tumor and LVI (+); n = 29], and high risk [50 % or greater presence of yolk sac tumor and LVI (+); n = 8]. Relapse rates of the low-risk, intermediate-risk, and high-risk groups were 7.3, 31.0, and 75.0 %, respectively. LVI and a predominant presence of yolk sac tumor are crucial risk factors for relapse of CSI NSGCT. For patients without either of these risk factors, active surveillance post-orchiectomy is a safe and effective approach for the initial management of CSI NSGCT.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 058943677

Download citation: RISBibTeXText

PMID: 25471669

DOI: 10.1007/s00345-014-1454-7


Related references

Surveillance in patients with stage I testicular nonseminomatous germ cell tumors. Cancer Investigation 11(1): 10-14, 1993

Surveillance study for clinical stage I testicular seminomas and nonseminomatous germ cell tumors. International Journal of Urology 5(6): 568-574, 1998

Five years experience with orchiectomy alone surveillance for clinical stage i nonseminomatous germ cell testicular tumors. Journal of Urology 137(4 Part 2): 211A, 1987

Outcomes of surveillance versus adjuvant chemotherapy for patients with stage IA and IB nonseminomatous testicular germ cell tumors. World Journal of Urology 35(7): 1103-1110, 2016

The case for observation of patients with clinical stage I nonseminomatous germ cell testicular tumors. Seminars in Urology 11(2): 92-98, 1993

Non-risk-adapted surveillance for patients with stage I nonseminomatous testicular germ-cell tumors: diminishing treatment-related morbidity while maintaining efficacy. Annals of Oncology 21(6): 1296-1301, 2010

DNA ploidy in the primary tumor from patients with nonseminomatous testicular germ cell tumors clinical stage I. Cancer 67(7): 1874-1877, 1991

Risk factors for relapse in patients with clinical stage I testicular nonseminomatous germ cell tumors. Medical Oncology 30(1): 494, 2013

Surveillance alone for patients with clinical stage 1 nonseminomatous germ cell tumors of the testis preliminary results. Journal of Urology 131(3): 491-493, 1984

Surveillance Alone for Patients with Clinical Stage I Nonseminomatous Germ Cell Tumors of the Testis: Preliminary Results. The Journal of Urology 131(3): 491-493, 1984

MIB-1 immunohistochemistry in clinical stage I nonseminomatous testicular germ cell tumors predicts patients at low risk for metastasis. Cancer. 79(9): 1710-1716, 1997

Importance of a new tumor marker TRA-1-60 in the follow-up of patients with clinical stage I nonseminomatous testicular germ cell tumors. Annals of Surgical Oncology 4(4): 321-327, 1997

MIB-1 Immunohistochemistry in Clinical Stage I Nonseminomatous Testicular Germ Cell Tumors Predicts Patients at Low Risk for Metastasis. Journal of Urology 160(6): 2291-2292, 1998

Serum lactate dehydrogenase isoenzyme 1 and relapse in patients with nonseminomatous testicular germ cell tumors clinical stage I. Acta Oncologica 40(4): 536-540, 2001

Management of patients with clinical stage I nonseminomatous germ cell testicular cancer: Active surveillance versus adjuvant chemotherapy - single-centre experience. Neoplasma 62(1): 159-163, 2014